Bank of America Corp DE Sells 82,674 Shares of uniQure N.V. $QURE

Key Points

• Bank of America reduced its uniQure position by 25.1%, selling 82,674 shares during the first quarter and retaining 246,851 shares worth approximately $4.0 million.
• Analyst sentiment remains broadly positive: 13 analysts rate QURE a Buy, three Hold, and one Sell, producing a Moderate Buy consensus with an average price target of $65 versus a recent price of $48.72.
• uniQure reported a quarterly loss of $1.22 per share, missing estimates of $0.82, although revenue of $5.84 million exceeded expectations. Insiders also sold 388,229 shares worth $16.8 million over the past three months.

Bank of America Corp DE decreased its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 25.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 246,851 shares of the biotechnology company's stock after selling 82,674 shares during the period. Bank of America Corp DE owned approximately 0.39% of uniQure worth $4,036,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in QURE. Arizona State Retirement System raised its position in uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 627 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock worth $87,000 after acquiring an additional 650 shares during the period. CIBC Private Wealth Group LLC bought a new position in uniQure during the 3rd quarter worth about $50,000. Torren Management LLC purchased a new position in uniQure during the 4th quarter valued at about $28,000. Finally, IFP Advisors Inc bought a new stake in shares of uniQure in the 4th quarter valued at about $48,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wolfe Research raised uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a research report on Wednesday, July 29th. Weiss Ratings reiterated a "sell (e+)" rating on shares of uniQure in a research note on Friday, June 26th. Barclays cut their price target on shares of uniQure from $65.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, July 30th. Leerink Partners raised their price objective on uniQure from $36.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, June 18th. Finally, Cantor Fitzgerald upgraded uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 target price on the stock in a research note on Wednesday, June 17th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $65.00.

Insider Buying and Selling

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the firm's stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares of the company's stock, valued at $1,949,025.24. This trade represents a 21.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of uniQure stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer owned 519,227 shares in the company, valued at approximately $23,448,291.32. This represents a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 388,229 shares of company stock worth $16,817,099 in the last three months. Company insiders own 4.65% of the company's stock.

uniQure Trading Down 1.7%

Shares of QURE stock opened at $48.72 on Friday. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $3.38 billion, a price-to-earnings ratio of -12.15 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The stock has a 50 day simple moving average of $44.44 and a 200-day simple moving average of $29.54.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter last year, the company earned ($0.69) EPS. On average, equities research analysts expect that uniQure N.V. will post -3.74 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.